Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human fetal ganglionic eminence cells
- Development stage
- Discontinued
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Cell Therapies
- Administration
- Intracerebral
01
Overview
Human fetal ganglionic eminence cells are an experimental cell therapy investigated for the treatment of Huntington's disease. Developed by Assistance Publique - Hôpitaux de Paris (AP-HP), this approach involves the surgical intrastriatal transplantation of primary neurons derived from the fetal ganglionic eminence, which is the developmental precursor to the striatum. The therapeutic goal is to replace degenerated GABAergic medium spiny neurons and restore the functional integrity of the striatal-cortical circuits in patients with early-stage disease. This therapy was evaluated in the Multicentric Intracerebral Grafting in Huntington's Disease (MIG-HD) Phase II trial, a randomized, delayed-start study. However, the trial failed to demonstrate a significant clinical benefit compared to the control group, and some patients experienced graft-related complications such as alloimmunization and rejection.
- Other names
- graft intracerebral of foetal neuronsfetal striatal neuronshuman fetal striatal transplantationintrastriatal transplantation of human fetal ganglionic eminence cells
Beyond the preview
Go deeper on human fetal ganglionic eminence cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human fetal ganglionic eminence cells.